Borea Therapeutics is an innovative biotech start-up located in Milan, and co-founded by Professor Paul Heppenstall and EMBLEM, the technology transfer partner of EMBL (European Molecular Biology Laboratory), and backed by Sofinnova Partners.
Borea Therapeutics’ technology, based upon chemical modification of adeno-associated viral vectors (AAV) builds on scientific discoveries generated at EMBL.